Libby P, Ridker PM, Maseri A. Inflammation and athero- sclerosis. Circulation 2002;105:1135-43.
Frayn KN, Fielding BA, Karpe F. Adipose tissue fatty acid metabolism and cardiovascular disease. Curr Opin Lipidol 2005;16:409-15.
Trayhurn P, Wood IS. Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem Soc Trans 2005;33:1078-81.
Lin RY, Reis ED, Dore AT, et al. Lowering of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholes- terolemic mice. Atherosclerosis 2002;163:303-11.
Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004;63:582-92.
Uribarri J, Cai W, Sandu O, et al. Diet-derived advanced glycation end products are major contributors to the body’s AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci 2005;1043:461-6.
Gey KF, Moser UK, Jordan P, et al. Increased risk of cardiovascular disease at suboptimal plasma concentra- tions of essential antioxidants: an epidemiological update with special attention to carotene and vitamin C. Am J Clin Nutr 1993;57:787-97.
Nickander KK, McPhee BR, Low PA, Tritschler H. Alpha-lipoic acid: antioxidant potency against lipid per oxidation of neural tissues in vitro and implications for diabetic neuropathy. Free Radic Biol Med 1996;21:631-9.
Packer L, Tritschler HJ, Wessel K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med 1997;22:359-78.
Thirunavukkarasu V, Anuradha CV. Influence of alpha- lipoic acid on lipid peroxidation and antioxidant defence system in blood of insulin-resistant rats. Diabetes Obes Metab 2004;6:200-7.
Thirunavukkarasu V, Anitha Nandhini AT, Anuradha CV. Cardiac lipids and antioxidant status in high fructose rats and the effect of alpha-lipoic acid. Nutr Metab Cardiovasc Dis 2004;14:351-7.
Devaraj S, Tang R,Adams-Huet B, et al. Effect of high-dose alpha-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease. Am J Clin Nutr 2007;86:1392-8.
Wilkinson IB, Megson IL, MacCallum H, et al. Oral vitamin C reduces arterial stiffness and platelet aggrega- tion in humans. J Cardiovasc Pharmacol 1999;34:690-3.
Devaraj S, Leonard S, Traber MG, et al. Gamma-tocopherol supplementation alone and in combination with alpha- tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome. Free Radic Biol Med 2008;44:1203-8.
Reiter E, Jiang Q, Christen S. Anti-inflammatory prop- erties of alpha- and gamma-tocopherol. Mol Aspects Med 2007;28:668-91.
Helzlsouer KJ, Huang HY, Alberg AJ, et al. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 2000;92:2018-23.
Dietrich M, Traber MG, Jacques PF, et al. Does gamma- tocopherol play a role in the primary prevention of heart disease and cancer? A review. J Am Coll Nutr 2006;25:292-9.
Killilea DW, Ames BN. Magnesium deficiency acceler- ates cellular senescence in cultured human fibroblasts. Proc Natl Acad Sci U S A 2008;105:5768-73.
Frank B, Gupta S. A review of antioxidants and Alzheimer’s disease. Ann Clin Psychiatry 2005;17:269-86.
Cole GM, Lim GP, Yang F, et al. Prevention of Alzheimer’s disease: Omega-3 fatty acid and phenolic anti-oxidant interventions. Neurobiol Aging 2005;26:133-6.
Iqbal M, Sharma SD, Okazaki Y, et al. Dietary supple- mentation of curcumin enhances antioxidant and phase II metabolizing enzymes in ddY male mice: possible role in protection against chemical carcinogenesis and toxicity. Pharmacol Toxicol 2003;92:33-8.
Religa D, Styczynska M, Peplonska B, et al. Homocysteine apolipoproteine E and methylenetetrahydrofolate reduc- tase in Alzheimer’s disease and mild cognitive impair- ment. Dement Geriatr Cogn Disord 2003;16:64-70.
Selley ML. Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentra-tions of nitric oxide in the plasma of patients with Alzheimer’s disease.Neurobiol Aging2003;24:903-7.
Reutens S, Sachdev P. Homocysteine in neuropsychiatric disorders of the elderly. Int J Geriatr Psychiatry 2002;17: 859-64.
McCaddon A, Davies G, Hudson P, et al. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 1998;13:235-9.
Auer J, Berent R, Weber T, et al. Homocysteine and cardiovascular risk. Wien Med Wochenschr 2001;151:25-8.
Dzielinska Z, Kadziela J, Sitkiewicz D, et al. Elevated levels of homocysteine in plasma as a risk factor for coro- nary artery disease. Pol Arch Med Wewn 2000;104:345-53.
Kuo HK, Sorond FA, Chen JH, et al. The role of homocys- teine in multisystem age-related problems: a systematic review. J Gerontol A Biol Sci Med Sci 2005;60:1190-201.
Yuneva MO, Bulygina ER, Gallant SC, et al. Effect of carnosine on age-induced changes in senescence-acceler- ated mice. J Anti-Aging Med 1999;2:337-42
Gallant S, Kukley M, Stvolinsky S, et al. Effect of carno- sine on rats under experimental brain ischemic. Tohoku J Exp Med 2000;191:85-99.
Munch G, Mayer S, Michaelis J, et al. Influence of advanced glycation end- products and AGE-inhibitors on nucleation-dependent polymerization of beta- amyloid peptide. Biochim Biophys Acta 1997;1360:17-29.
Brownson C, Hipkiss AR. Carnosine reacts with a glycated protein. Free Radic Biol Med 2000;28:1564-70.
Hipkiss AR, Brownson C. A possible new role for the anti-aging peptide carnosine. Cell Mol Life Sci 2000;57: 747-53.
